Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin after primary PCI in STEMI with type 2 diabetes
ChiCTR2100049306Phase 4Not yet recruiting
- Sponsor
- Tianjin Chest Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in myocardial infarction (MI) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tianjin Chest Hospital. Primary endpoint: Infarct area as a percentage of left ventricular size. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100049306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049306.